PharmaCyte Biotech (EFYA) Stock Price & Analysis

2 Followers

EFYA Stock Chart & Stats

€2.52€0.00(0.00%)

At close: Nov 06 5:30 PM GMT+1

Day’s Range: EUR 2.52 - EUR 2.54
52-Week Range: EUR 2.52 - EUR 2.54
Previous Close: EUR 2.52
Volume: N/A
Average Volume (3M): 500
Market Cap: EUR 3.47M
Enterprise Value: -EUR 14.82T
Total Cash (Recent Filing): EUR 30.51M
Total Debt (Recent Filing): EUR 0
Price to Earnings (P/E): ―
Beta: N/A
Next Earnings: N/A
EPS Estimate: N/A
Next Dividend Ex-Date: N/A
Dividend Yield: N/A

PharmaCyte Biotech News

PharmaCyte Biotech Shareholders Approve Governance and Equity Actions

PharmaCyte Biotech ( ($PMCB) ) has provided an update. On March 30, 2026, PharmaCyte Biotech, Inc. held its annual meeting of stockholders via live webcast, with about 55% of eligible

7M ago8K PMCB

Largest borrow rate increases among liquid names

Latest data shows the largest indicative borrow rate increases among liquid option names include: Sellas Life Sciences (SLS) 534.91% +52.88, Cipher Mining (CIFR) 4.04% +3.56, PharmaCyte Biotech (PMCB) 90.49% +2.80,

10M agoBTQ IRE

Largest borrow rate increases among liquid names

Latest data shows the largest indicative borrow rate increases among liquid option names include: PharmaCyte Biotech (PMCB) 96.86% +3.59, BTQ Technologies Corp. Common Stock (BTQ) 64.68% +2.49, Reviva Pharmaceuticals Holdings

10M agoBTQ BILI

Largest borrow rate increases among liquid names

Latest data shows the largest indicative borrow rate increases among liquid option names include: BigBearai Holdings (BBAI) 13.64% +9.54, Sellas Life Sciences (SLS) 67.67% +9.53, T-REX 2X LONG MSTR DAILY

10M agoNFE SLS

PharmaCyte Biotech Delays Quarterly Report Filing

PharmaCyte Biotech ( ($PMCB) ) has released a notification of late filing. PharmaCyte Biotech, Inc. has announced a delay in filing its Form 10-Q (Quarter Report) for the financial period

10M agoPMCB EFYA

Largest borrow rate increases among liquid names

Latest data shows the largest indicative borrow rate increases among liquid option names include: PharmaCyte Biotech (PMCB) 279.47% +3.85, Nano Nuclear Energy Inc (NNE) 76.92% +3.32, Itau Unibanco (ITUB) 4.11%

10M agoNNE STM

PharmaCyte Biotech Faces Nasdaq Non-Compliance Notice

PharmaCyte Biotech ( ($PMCB) ) just unveiled an update. On December 1, 2025, PharmaCyte Biotech received a notice from Nasdaq indicating non-compliance with the minimum bid price requirement, as its

11M ago8K PMCB

PharmaCyte sells Femasys stake, sees cash position rising to $20M

PharmaCyte Biotech (PMCB) announced the successful monetization of its stake in Femasys (FEMY). Following the monetization of the stake, PharmaCyte’s cash and marketable securities are expected to increase to approximately

11M agoFEMY PMCB

PharmaCyte Biotech Amends Equity Incentive Plan

PharmaCyte Biotech ( ($PMCB) ) just unveiled an announcement. On October 30, 2025, PharmaCyte Biotech held a special meeting where stockholders approved an amendment to the 2022 Equity Incentive Plan,

1y ago8K PMCB

PharmaCyte Biotech Boosts Investment in TNF Pharmaceuticals

PharmaCyte Biotech ( ($PMCB) ) has issued an update. On September 2, 2025, PharmaCyte Biotech, Inc. announced an increased investment of $3 million in TNF Pharmaceuticals to support TNF’s acquisition

1y ago8K PMCB

PharmaCyte Biotech increases stake in TNF Pharmaceuticals by $3M

PharmaCyte Biotech (PMCB) announced that it has increased its stake in TNF Pharmaceuticals (TNFA) by an additional $3M. The company does so to help support TNF’s recent acquisition of a

1y agoPMCB TNFA

PharmaCyte Biotech Secures $7 Million Private Placement

PharmaCyte Biotech ( ($PMCB) ) has issued an update. On August 17, 2025, PharmaCyte Biotech, Inc. announced a $7 million private placement financing with existing investors, involving the sale of

1y ago8K PMCB

PharmaCyte Biotech Delays Yearly Report Filing

PharmaCyte Biotech ( ($PMCB) ) has released a notification of late filing. PharmaCyte Biotech, Inc. has announced a delay in filing its Form 10-K (Yearly Report) for the fiscal year

1y agoPMCB EFYA

MyMD Pharmaceuticals secures $7M investment from PharmaCyte Biotech

MyMD Pharmaceuticals (MYMD) announced that it has secured $7M in commitments in two private placement funding rounds led by a strategic investor, PharmaCyte Biotech (PMCB), a clinical-stage biotechnology company developing

2y agoMYMD PMCB

EFYA FAQ

What was PharmaCyte Biotech’s price range in the past 12 months?

PharmaCyte Biotech lowest stock price was €2.52 and its highest was €2.54 in the past 12 months.

What is PharmaCyte Biotech’s market cap?

PharmaCyte Biotech’s market cap is €3.47M.

When is PharmaCyte Biotech’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

How were PharmaCyte Biotech’s earnings last quarter?

PharmaCyte Biotech released its earnings results on Mar 16, 2022. The company reported -€0.035 earnings per share for the quarter, beating the consensus estimate of -€0.044 by €0.009.

Is PharmaCyte Biotech overvalued?

Not enough analysts have published a price target to calculate whether the price is overvalued.

Does PharmaCyte Biotech pay dividends?

PharmaCyte Biotech does not currently pay dividends.

What is PharmaCyte Biotech’s EPS estimate?

PharmaCyte Biotech’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does PharmaCyte Biotech have?

PharmaCyte Biotech has 10,735,649 shares outstanding.

What happened to PharmaCyte Biotech’s price movement after its last earnings report?

PharmaCyte Biotech reported an EPS of -€0.035 in its last earnings report, beating expectations of -€0.044. Following the earnings report the stock price went same ―.

Which hedge fund is a major shareholder of PharmaCyte Biotech?

Hedge funds hold PharmaCyte Biotech shares: the largest hedge-fund position in PharmaCyte Biotech is 2,130,865,844 shares, and hedge funds decreased their holdings by 2.0 shares last quarter.

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

PharmaCyte Biotech

PharmaCyte Biotech, Inc. is a biotechnology firm dedicated to the development and commercialization of advanced cellular therapies within the United States. Their primary therapeutic areas include various forms of cancer, diabetes, and malignant ascites. Central to their efforts is Cell-in-a-Box, their proprietary encapsulation technology which utilizes cellulose to enclose live cells. This innovative platform serves as the foundation for treatments aimed at diverse cancers, such as advanced and inoperable pancreatic cancer, as well as diabetes. The company's pipeline includes therapies for pancreatic and other solid cancerous tumors; a treatment for Type 1 and insulin-dependent Type 2 diabetes involving encapsulated, genetically modified insulin-producing cells; and cancer treatments derived from cannabis plant compounds. To further its research, PharmaCyte maintains collaborative agreements: one with the University of Technology, Sydney, for the creation of melligen cells to combat diabetes, and another with the University of Northern Colorado, focusing on methods for identifying, separating, and quantifying cannabis constituents. Originally established in 1996, the company operated under the name Nuvilex, Inc. before rebranding as PharmaCyte Biotech, Inc. in January 2015. Its corporate headquarters are located in Las Vegas, Nevada.

PharmaCyte Biotech (EFYA) Earnings & Revenues

Historic Earnings Reports

Technical Analysis

Overall Consensus

Indicator	Bullish	Neutral	Bearish
Overall Consensus	6	5	4
Technical Analysis	2	1	0
Moving Averages	4	4	4

Technical Analysis >

Similar Stocks

Stocks similar to DE:EFYA
Company	Price & Change	Follow
CLRBCellectar Biosciences
MRKRMarker Therapeutics
MBIOMustang Bio
NCNANucana
CELUCelularity

Compare DE:EFYA Stocks >

Ownership Overview

6.93% Insiders
1.51% Mutual Funds
0.21% Other Institutional Investors
90.82% Public Companies and Individual Investors

Detailed Ownership Overview >

Popular Stocks

Popular Stocks
Company	Price & Change	Follow
NVDANvidia
AAPLApple
MSFTMicrosoft

EFYA Stock Chart & Stats

PharmaCyte Biotech News

PharmaCyte Biotech Shareholders Approve Governance and Equity Actions

Largest borrow rate increases among liquid names

Largest borrow rate increases among liquid names

Largest borrow rate increases among liquid names

PharmaCyte Biotech Delays Quarterly Report Filing

Largest borrow rate increases among liquid names

PharmaCyte Biotech Faces Nasdaq Non-Compliance Notice

PharmaCyte sells Femasys stake, sees cash position rising to $20M

PharmaCyte Biotech Amends Equity Incentive Plan

PharmaCyte Biotech Boosts Investment in TNF Pharmaceuticals

PharmaCyte Biotech increases stake in TNF Pharmaceuticals by $3M

PharmaCyte Biotech Secures $7 Million Private Placement

PharmaCyte Biotech Delays Yearly Report Filing

MyMD Pharmaceuticals secures $7M investment from PharmaCyte Biotech

EFYA FAQ

Company Description

PharmaCyte Biotech

PharmaCyte Biotech (EFYA) Earnings & Revenues

Technical Analysis

Overall Consensus

Similar Stocks

Ownership Overview

Popular Stocks

Become an Expert with TipRanks Premium